NeuralBase AI Submits HeartEase App for Google Play Store Review, Expanding Access to AI-Powered Heart Health Support

NeuralBase AI Ltd., trading under the ticker symbol NBBI on the OTC Markets, has taken a significant step towards broadening the accessibility of its HeartEase mobile application by submitting it for review on the Google Play Store. This move is poised to bring advanced, AI-powered health and wellness support to Android users globally, offering real-time insights and personalized guidance for heart health.

The HeartEase app represents a pivotal innovation in the intersection of technology and healthcare, leveraging artificial intelligence to empower individuals with tools for monitoring and improving their heart health. Following the anticipated approval and launch on the Google Play Store, NeuralBase AI plans to extend the app's availability to iOS users through the Apple App Store, further democratizing access to its features.

Vighnesh Dobale, CEO of NeuralBase AI, expressed enthusiasm about the app's potential impact, stating, 'We are thrilled to bring HeartEase to the Android community and look forward to its imminent launch. This is just the first step in our broader vision to make AI-driven healthcare support available to everyone, on every platform.'

For those interested in learning more about NeuralBase AI Ltd. and its initiatives, additional information can be found by visiting https://www.neuralbase.ai or through the U.S. Securities and Exchange Commission's EDGAR database at https://www.sec.gov.

This development underscores the growing role of artificial intelligence in transforming healthcare delivery, offering scalable solutions that can enhance patient outcomes and streamline access to vital health information. The submission of the HeartEase app for Google Play Store review marks a critical milestone in NeuralBase AI's mission to integrate cutting-edge technology with everyday health management.